Medtronic (NYSE:MDT) announced today that it launched its Carpediem cardio-renal pediatric dialysis emergency machine in the U.S.
Fridley, Minn.-based Medtronic’s Carpediem machine received FDA de novo clearance in May for providing continuous dialysis in critically ill young children. The first-of-its-kind machine is indicated for use in acute kidney injury or fluid-overloaded patients requiring hemodialyiss or hemofiltration therapy.
The first Carpediem machines, intended to provide continuous renal replacement therapy (CRRT) to patients between 2.5 kg and 10 kg, were successfully installed and are in use at Cincinnati Children’s Hospital Medical Center now, according to a news release.
Carpediem is intended to address challenges associated with current machines for neonatal patients, Medtronic said.
“At Medtronic, we strive to provide a portfolio of renal care solutions that improve outcomes, access to care, and quality of life for patients affected by severe renal injury or disease globally — no matter their size or age,” Medtronic president of renal care solutions Ven Manda said in the release. “For the first time, some of the tiniest and most vulnerable patients can be treated with technology designed specifically for them.”